LONDON and PHILADELPHIA – October 23, 2025 – Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, announces the team will present the published data of the platform innovation, the pre|CISION® dual payload peptide drug conjugate (PDC) delivery system, following their return from the 2025 AACR-NCI-EORTC International Molecular Targets Congress.
Christina Coughlin, Chief Executive Officer, David Liebowitz, Chief Medical Officer, Francis Wilson, VP Chemistry and Ruairidh Edwards, Translational Scientist will deliver a presentation via Investor Meet Company at 16:00 BST on Wednesday October 29, 2025.
The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC here.
Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until October 28 09:00 BST, or at any time during the recorded presentation.